“Three medicines and three formulas” in COVID-19: from bench to bedside

Abstract

Chinese guideline has proven effective in the fight against coronavirus disease 2019 (COVID-19) during the global spread of the epidemic. Traditional Chinese medicine (TCM) is widely recognized for its effectiveness in alleviating symptoms, inhibiting disease progress, reducing mortality, and improving the cure rate of patients with COVID-19. During the pandemic, “three medicines and three formulas” (TMTFs) stood out from hundreds of others in registered clinical studies, which became highly recommended as TCM for COVID-19 treatment. The TMTFs not only effectively relieve the clinical symptoms of fever, cough, fatigue, and phlegm, but also substantially shorten the time of nucleic acid negative conversion, improve lung computed tomography imaging features and inflammation, ameliorate clinical biochemical indicators, and reduce sequelae. Their potential pharmacological mechanisms are mainly related to the crosstalk between viral toxicity, endothelial damage, cytokine storm, immune response, and microthrombus. In brief, the clinical effects and the potential mechanisms of TMTFs on COVID-19 were systematically analyzed and summarized covering the entirety of disease development, including virus invasion and replication, immune response and cytokine storm, and acute respiratory distress syndrome and multiple organ dysfunction syndrome. This review provides a theoretical basis and reference for the in-depth understanding of the positive role of TMTFs in COVID-19 treatment.

Keywords

Clinical research / COVID-19 / Potential mechanism / SARS-CoV-2 / Three medicines and three formulas

References

[[1]] Chen N, Zhou M, Dong X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.

[[2]] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

[[3]] Zhang S, Wang Z, Chang R, et al.COVID-19 containment: China provides important lessons for global response. Front Med. 2020;14(2):215-219.

[[4]] Feng ZH, Cheng Y-R, Chen J, et al.Chinese medical personnel against the 2019-nCoV. J Infect. 2020;80(5):578-606.

[[5]] Zhao C, Li Li, Yang W, et al.Chinese medicine formula Huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne). 2021;8:696976.

[[6]] Ren JL, Zhang AH, Wang XJ.Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res. 2020;155:104743.

[[7]] Xiong Y, Tian Y, Ma Y, et al.The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: a retrospective cohort study. Phytomedicine. 2022;95:153868.

[[8]] Que H, Hong W, Lan T, et al.Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment. Signal Transduct Target Ther. 2022;7(1):399.

[[9]] Ye L, et al.Potential herb-drug interactions between anti-COVID-19 drugs and traditional Chinese medicine. Acta Pharm Sin B. 2023.

[[10]] Xian Y, Zhang J, Bian Z, et al.Bioactive natural compounds against human coronaviruses: a review and perspective. Acta Pharm Sin B. 2020;10(7):1163-1174.

[[11]] Yu S, Zhu Y, Xu J, et al.Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine. 2021;85:153364.

[[12]] Li BH, Li Z-Y, Liu M-M, et al.Progress in traditional Chinese medicine against respiratory viruses: a review. Front Pharmacol. 2021;12:743623.

[[13]] Lyu M, Fan G, Xiao G, et al.Traditional Chinese medicine in COVID-19. Acta Pharm Sin B. 2021;11(11):3337-3363.

[[14]] Leung EL, Pan H-D, Huang Y-F, et al.The scientific foundation of Chinese herbal medicine against COVID-19. Engineering (Beijing). 2020;6(10):1099-1107.

[[15]] Luo H, Gao Y, Zou J, et al.Reflections on treatment of COVID-19 with traditional Chinese medicine. Chinese Med. 2020;15:94.

[[16]] Huang K, Zhang P, Zhang Z, et al.Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther. 2021;225:107843.

[[17]] An X, Xu X, Xiao MZ, et al.Efficacy of Jinhua Qinggan granules combined with western medicine in the treatment of confirmed and suspected COVID-19: a randomized controlled trial. Front Med (Lausanne). 2021;8:728055.

[[18]] Liu Z, Li X, Gou C, et al.Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients. J Tradit Chin Med. 2020;40(3):467-472.

[[19]] Shah MR, Fatima S, Khan SN, et al.Jinhua Qinggan granules for non-hospitalized COVID-19 patients: a double-blind, placebo-controlled, and randomized controlled trial. Front Med (Lausanne). 2022;9:928468.

[[20]] Gao D, Niu M, Wei S-Z, et al.Identification of a pharmacological biomarker for the bioassay-based quality control of a thirteen-component TCM formula (Lianhua Qingwen) used in treating influenza A virus (H1N1) infection. Front Pharmacol. 2020;11:746.

[[21]] Shen X, Yin F.The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule. Biomed Pharmacother. 2021;142:111998.

[[22]] Liu M, Gao Y, Yuan Y, et al.Efficacy and safety of integrated traditional Chinese and Western medicine for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res. 2020;158:104896.

[[23]] Wang DC, Yu M, Xie W-X, et al.Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019. J Integr Med. 2022;20(1):26-33.

[[24]] Hu K, Guan W-J, Bi Y, et al.Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. 2021;85:153242.

[[25]] Hu C, He B, Gong F, et al.The adverse reactions of Lianhua Qingwen capsule/granule compared with conventional drug in clinical application: a meta-analysis. Front Pharmacol. 2022;13:764774.

[[26]] Xiao M, Tian J, Zhou Y, et al.Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial. Pharmacol Res. 2020;161:105126.

[[27]] Li L, Yu X, Xie D, et al.Influence of traditional Chinese medicines on the in vivo metabolism of lopinavir/ritonavir based on UHPLC-MS/MS analysis. J Pharm Anal. 2022;12(2):270-277.

[[28]] Li X, Yang Y, Liu L, et al.Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019. Pharmacol Res. 2020;160:105036.

[[29]] Qiao Y, Xu X, Zhou F, et al.Effect of Lianhua Qingwen capsules on the positive rate of COVID-19 close contacts: a retrospective analysis of a large-scale population-based cohort study. Phytomedicine. 2023;112:154690.

[[30]] Pan X, Dong L, Yang L, et al.Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. Virus Res. 2020;286:198057.

[[31]] Xiong WZ, Wang G, Du J, et al.Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: a pilot randomized clinical trial. Integr Med Res. 2020;9(3):100489.

[[32]] Li C, Wang P, Li M, et al.The current evidence for the treatment of sepsis with Xuebijing injection: bioactive constituents, findings of clinical studies and potential mechanisms. J Ethnopharmacol. 2021;265:113301.

[[33]] Wu Q, Yin C-H, Li Y, et al.Detecting critical functional ingredients group and mechanism of Xuebijing injection in treating sepsis. Front Pharmacol. 2021;12:769190.

[[34]] Zhou W, Lai X, Wang X, et al.Network pharmacology to explore the anti-inflammatory mechanism of Xuebijing in the treatment of sepsis. Phytomedicine. 2021;85:153543.

[[35]] Fan TT, Cheng B-L, Fang X-M, et al.Application of Chinese medicine in the management of critical conditions: a review on sepsis. Am J Chin Med. 2020;48(6):1315-1330.

[[36]] Guo H, Zheng J, Huang G, et al.Xuebijing injection in the treatment of COVID-19: a retrospective case-control study. Ann Palliat Med. 2020;9(5):3235-3248.

[[37]] Song Y, Yao C, Yao Y, et al.XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med. 2019;47(9):e735-e743.

[[38]] Zhang C, He H, Chen X, et al.The prediction of lymphocyte count and neutrophil count on the efficacy of Xuebijing adjuvant treatment for severe community-acquired pneumonia: a post hoc analysis of a randomized controlled trial. Phytomedicine. 2023;110:154614.

[[39]] Luo Z, Chen W, Xiang M, et al.The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med. 2021;42:101305.

[[40]] Ma Q, Qiu M, Zhou H, et al.The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical coronavirus disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2. Pharmacol Res. 2020;160:105073.

[[41]] Song Y, Zhang M, Yin L, et al.COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents. 2020;56(2):106080.

[[42]] Wang Y, Lu C, Li H, et al.Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: a retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China. J Ethnopharmacol. 2021;277:113888.

[[43]] Xia Y, Wang X, Wu W, et al.Rehabilitation of sepsis patients with acute kidney injury based on intelligent medical big data. J Healthc Eng. 2022;2022:8414135.

[[44]] Zhu Y, Han Q, Wang L, et al.Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-kappaB pathway. J Ethnopharmacol. 2023;301:115763.

[[45]] Niu M, Wang R-L, Wang Z-X, et al.Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking. Zhongguo Zhong Yao Za Zhi. 2020;45(6):1213-1218.

[[46]] Chen B, Xue Y, Jing H, et al.Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: a prospective, non-randomized, controlled trial. Integr Med Res. 2023;12(2):100950.

[[47]] Chen CY, et al.Efficacy and safety of Huashi Baidu granules in treating patients with SARS-CoV-2 omicron variant: a single-center retrospective cohort study. Chin J Integr Med. 2023:1-8.

[[48]] Chen X, Wu Y, Chen C, et al.Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Acta Pharm Sin B. 2021;11(1):222-236.

[[49]] Shi N, Guo L, Liu B, et al.Efficacy and safety of Chinese herbal medicine versus lopinavir-ritonavir in adult patients with coronavirus disease 2019: a non-randomized controlled trial. Phytomedicine. 2021;81:153367.

[[50]] Ren W, Ma Y, Wang R, et al.Research advance on Qingfei Paidu decoction in prescription principle, mechanism analysis and clinical application. Front Pharmacol. 2020;11:589714.

[[51]] Shi N, Liu B, Liang N, et al.Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res. 2020;161:105290.

[[52]] Zhang L, Zheng X, Bai X, et al.Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: a national retrospective registry study. Phytomedicine. 2021;85:153531.

[[53]] Zhang K.Is traditional Chinese medicine useful in the treatment of COVID-19? Am J Emerg Med. 2020;38(10):2238.

[[54]] Xin S, Cheng X, Zhu B, et al.Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment. Biomed Pharmacother. 2020;129:110500.

[[55]] Zong X, Liang N, Wang J, et al.Treatment effect of Qingfei Paidu decoction combined with conventional treatment on COVID-19 patients and other respiratory diseases: a multi-center retrospective case series. Front Pharmacol. 2022;13:849598.

[[56]] Li X, et al.Computational analysis illustrates the mechanism of Qingfei Paidu decoction in blocking the transition of COVID-19 patients from mild to severe stage. Curr Gene Ther. 2021.

[[57]] Zhang L, Ma Y, Shi N, et al.Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: a systematic review and meta-analysis. Phytomedicine. 2022;102:154166.

[[58]] Wang X, Ma T, Zhang W, et al.Effectiveness and safety research of Qingfei Paidu (QFPD) in treatment of COVID-19: an up-to-date systematic review and meta-analysis. Chin Med. 2022;17(1):122.

[[59]] Wrapp D, Wang N, Corbett KS, et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-1263.

[[60]] Niu W, Wu F, Cui H, et al.Network pharmacology analysis to identify phytochemicals in traditional Chinese medicines that may regulate ACE2 for the treatment of COVID-19. Evid Based Complement Alternat Med. 2020;2020:7493281.

[[61]] Shi M, Peng B, Li A, et al.Broad anti-viral capacities of Lian-Hua-Qing-Wen capsule and Jin-Hua-Qing-Gan granule and rational use against COVID-19 based on literature mining. Front Pharmacol. 2021;12:640782.

[[62]] Runfeng L, Yunlong H, Jicheng H, et al.Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761.

[[63]] Hong L, He M, Li S, et al.Predicting for anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of Lianhua Qingwen Capsules in treating COVID-19. Chin Med. 2022;17(1):84.

[[64]] Fu L, Shao S, Feng Y, et al.Mechanism of microbial metabolite Leupeptin in the treatment of COVID-19 by traditional Chinese medicine herbs. mBio. 2021;12(5):e0222021.

[[65]] Li Y, Wu Y, Li S, et al.Identification of phytochemicals in Qingfei Paidu decoction for the treatment of coronavirus disease 2019 by targeting the virus-host interactome. Biomed Pharmacother. 2022;156:113946.

[[66]] Zhao L, Liu H, Wang Y, et al.Multimodal identification by transcriptomics and multiscale bioassays of active components in Xuanfeibaidu formula to suppress macrophage-mediated immune response. Engineering (Beijing). 2021;20:63-76.

[[67]] Tao Q, Du J, Li X, et al.Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Dev Ind Pharm. 2020;46(8):1345-1353.

[[68]] Niu WH, Wu F, Cao W-Y, et al. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6. Biosci Rep.2021;41(1):BSR20202583.

[[69]] Kageyama Y, Aida K, Kawauchi K, et al.Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL-6 and IFN-γ: an open-label, single-arm pilot study. World Acad Sci J. 2021;4(1).

[[70]] Wu J, Wang Q, Yang L, et al.Potency of Lianhua Qingwen granule combined with paramivir sodium chloride injection in treating influenza and level changes of serum inflammatory factors. Am J Transl Res. 2021;13(6):6790-6795.

[[71]] Xia QD, Xun Y, Lu JL, et al.Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19. Cell Prolif. 2020;53(12):e12949.

[[72]] Zhou Y, Niu M, Zhang D, et al.Screening for anti-inflammation quality markers of Lianhua Qingwen capsule based on network pharmacology, UPLC, and biological activity. Front Pharmacol. 2021;12.

[[73]] Chen Y, Zhang C, Wang N, et al.Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs. Chin J Nat Med. 2023;21(5):383-400.

[[74]] Xu P, Yang Z, Du S, et al.Intestinal microbiota analysis and network pharmacology reveal the mechanism by which Lianhua Qingwen capsule improves the immune function of mice infected with influenza A virus. Front Microbiol. 2022;13:1035941.

[[75]] Chen G, Gao Y, Jiang Y, et al.Efficacy and safety of Xuebijing injection combined with ulinastatin as adjunctive therapy on sepsis: a systematic review and meta-analysis. Front Pharmacol. 2018;9:743.

[[76]] Xing Y, Hua Y-R, Shang J, et al.Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing injection in the treatment of coronavirus disease 2019. Chin J Nat Med. 2020;18(12):941-951.

[[77]] Tian S, Zheng N, Zu X, et al.Integrated hepatic single-cell RNA sequencing and untargeted metabolomics reveals the immune and metabolic modulation of Qing-Fei-Pai-Du decoction in mice with coronavirus-induced pneumonia. Phytomedicine. 2022;97:153922.

[[78]] Yang R, Liu H, Bai C, et al.Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): in silico and experimental study. Pharmacol Res. 2020;157:104820.

[[79]] Zhao J, Tian S, Lu D, et al.Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19. Phytomedicine. 2021;85:153315.

[[80]] Zhang Q, Yue S, Wang W, et al.Potential role of gut microbiota in traditional Chinese medicine against COVID-19. Am J Chin Med. 2021;49(4):785-803.

[[81]] Chen J, et al.Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Biomed Pharmacother. 2020;129:110281.

[[82]] Wu GS, Zhong J, Zheng N-N, et al.Investigation of modulating effect of Qingfei Paidu Decoction on host metabolism and gut microbiome in rats. Zhongguo Zhong Yao Za Zhi. 2020;45(15):3726-3739.

[[83]] Li L, Wang X, Guo X, et al.Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19. Front Pharmacol. 2022;13:1013428.

[[84]] Xu X, Han M, Li T, et al.Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-10975.

[[85]] Wang Z, Zhan J, Gao H.Computer-aided drug design combined network pharmacology to explore anti-SARS-CoV-2 or anti-inflammatory targets and mechanisms of Qingfei Paidu decoction for COVID-19. Front Immunol. 2022;13:1015271.

[[86]] Zhang F, Huang J, Liu W, et al.Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: implication of herb-drug interactions in COVID-19 pharmacotherapy. Food Chem Toxicol. 2021;149:111998.

[[87]] Zhang Y, Gu X, Zhou Y, et al.An integrative analysis of Qingfei Paidu Decoction for its anti-HCoV-229E mechanism in cold and damp environment based on the pharmacokinetics, metabolomics and molecular docking technology. Phytomedicine. 2023;108:154527.

[[88]] Wu G, Zhang W, Zheng N, et al.Integrated microbiome and metabolome analysis reveals the potential therapeutic mechanism of Qing-Fei-Pai-Du decoction in mice with coronavirus-induced pneumonia. Front Cell Infect Microbiol. 2022;12:950983.

[[89]] Xu X, Xia J, Zhao S, et al.Qing-Fei-Pai-Du decoction and wogonoside exert anti-inflammatory action through down-regulating USP14 to promote the degradation of activating transcription factor 2. FASEB J. 2021;35(9):e21870.

[[90]] Li Y, Li B, Wang P, et al.Traditional Chinese medicine, Qingfei Paidu decoction and Xuanfei Baidu decoction, inhibited cytokine production via NF-κB signaling pathway in macrophages: implications for coronavirus disease 2019 (COVID-19) therapy. Front Pharmacol. 2021;12:722126.

[[91]] Wang Z, Zhang J, Zhan J, et al.Screening out anti-inflammatory or anti-viral targets in Xuanfei Baidu Tang through a new technique of reverse finding target. Bioorg Chem. 2021;116:105274.

[[92]] Rovas A, Osiaevi I, Buscher K, et al.Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2021;24(1):145-157.

[[93]] Wang Y, Sang X, Shao R, et al.Xuanfei Baidu decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway. J Ethnopharmacol. 2022;283:114701.

[[94]] Li Z, Pan H, Yang J, et al.Xuanfei Baidu formula alleviates impaired mitochondrial dynamics and activated NLRP3 inflammasome by repressing NF-κB and MAPK pathways in LPS-induced ALI and inflammation models. Phytomedicine. 2023;108:154545.

[[95]] He Q, Shi Y, Xing H, et al.Modulating effect of Xuanfei Baidu granule on host metabolism and gut microbiome in rats. Front Pharmacol. 2022;13:922642.

[[96]] Yan H, Lu J, Wang J, et al.Prevention of cyclophosphamide-induced immunosuppression in mice with traditional Chinese medicine Xuanfei Baidu decoction. Front Pharmacol. 2021;12:730567.

[[97]] Wang X, Zhang J, Luo L, et al.Comparative pharmacokinetics of 24 major bioactive components in normal and ARDS rats after oral administration of Xuanfei Baidu granules. J Ethnopharmacol. 2022;296:115472.

[[98]] Cai Y, Zeng M, Chen YZ.The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking. Ann Palliat Med. 2021;10(4):3864-3895.

[[99]] Wei WL, Wu S-F, Li H-J, et al.Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS. Chin J Nat Med. 2021;19(6):473-480.

[[100]] Xu H, Li S, Liu J, et al.Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19. Proc Natl Acad Sci U S A. 2023;120(18):e2301775120.

[[101]] Wang Z, Gao H.Anti-inflammatory or anti-SARS-CoV-2 ingredients in Huashi Baidu decoction and their corresponding targets: target screening and molecular docking study. Arab J Chem. 2023;16(5):104663.

[[102]] Wang Y, Jin X, Fan Q, et al.Deciphering the active compounds and mechanisms of HSBDF for treating ALI via integrating chemical bioinformatics analysis. Front Pharmacol. 2022;13:879268.

[[103]] He DD, Zhang X-K, Zhu X-Y, et al.Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction. Comput Biol Med. 2021;131:104293.

[[104]] Dong MN, Xiao Y, Li Y-F, et al.Amelioration of paraquat-induced pulmonary fibrosis in mice by regulating miR-140-5p expression with the fibrogenic inhibitor Xuebijing. Int J Immunopathol Pharmacol. 2020;34:2058738420923911.

[[105]] Bi CF, Liu J, Hao SW, Xu ZX, et al.Xuebijing injection protects against sepsis-induced myocardial injury by regulating apoptosis and autophagy via mediation of PI3K/AKT/ mTOR signaling pathway in rats. Aging (Albany NY). 2023.

[[106]] Kim C, Sim H, Bae JS.Benzoylpaeoniflorin activates anti-inflammatory mechanisms to mitigate sepsis in cell-culture and mouse sepsis models. Int J Mol Sci. 2022;23(21).

[[107]] Zha YF, Xie J, Ding P, et al.Senkyunolide I protect against lung injury via inhibiting formation of neutrophil extracellular trap in a murine model of cecal ligation and puncture. Int Immunopharmacol. 2021;99:107922.

[[108]] Shang T, Zhang Z-S, Wang X-T, et al.Xuebijing injection inhibited neutrophil extracellular traps to reverse lung injury in sepsis mice via reducing Gasdermin D. Front Pharmacol. 2022;13:1054176.

[[109]] Lv J, Guo X, Zhao H, et al.Xuebijing administration alleviates pulmonary endothelial inflammation and coagulation dysregulation in the early phase of sepsis in rats. J Clin Med. 2022;11(22):6696.

[[110]] Wang T, Li S, Wu Y, et al.Mechanistic investigation of Xuebijing for treatment of paraquat-induced pulmonary fibrosis by metabolomics and network pharmacology. ACS Omega. 2021;6(30):19717-19730.

[[111]] He F, Wang J, Liu Y, et al.Xuebijing injection induces anti-inflammatory-like effects and downregulates the expression of TLR4 and NF-kappaB in lung injury caused by dichlorvos poisoning. Biomed Pharmacother. 2018;106:1404-1411.

[[112]] Qian D, Zhang Y.Influence of Xuebijing injection combined with cefoperazone sodium and sulbactam sodium in treating hepatitis B-induced liver cirrhosis complicated by spontaneous bacterial peritonitis: TNF-α, IL-18, IL-6, and hepatic function. Am J Transl Res. 2021.

[[113]] Cao L, Li Z, Ren Y, et al.Xuebijing protects against septic acute liver injury based on regulation of GSK-3beta pathway. Front Pharmacia. 2021;12:627716.

[[114]] Liu J, Wang Z, Lin J, et al.Xuebijing injection in septic rats mitigates kidney injury, reduces cortical microcirculatory disorders, and suppresses activation of local inflammation. J Ethnopharmacol. 2021;276:114199.

[[115]] Yang R, Yang H, Wei J, et al.Mechanisms underlying the effects of Lianhua Qingwen on sepsis-induced acute lung injury: a network pharmacology approach. Front Pharmacol. 2021;12:717652.

[[116]] Huang L, Li X, Gu X, et al.Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863-876.

[[117]] Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022.

[[118]] Lu ZH, Yang C-L, Yang G-G, et al.Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial. Infect Dis Poverty. 2021;10(1):31.

[[119]] Liu W, Huang J, Zhang F, et al.Comprehensive profiling and characterization of the absorbed components and metabolites in mice serum and tissues following oral administration of Qing-Fei-Pai-Du decoction by UHPLC-Q-Exactive-Orbitrap HRMS. Chin J Nat Med. 2021;19(4):305-320.

RIGHTS & PERMISSIONS

2023 Acupuncture and Herbal Medicine